$Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection$
QR Code

QR Code

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection

Saved in:

Bibliographic Details
Format:	article
Language:	EN
Published:	BMJ Publishing Group 2021
Subjects:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/24e833b84a2d4da1adf17f8a9835304d
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
by: Weijie Li, et al.
Published: (2021)

Effects of systemic inflammation on relapse in early breast cancer
by: Nicholas P. McAndrew, et al.
Published: (2021)

Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
by: Matthew A. Wall, et al.
Published: (2021)

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
by: Michael Bitzer, et al.
Published: (2021)

Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
by: Ali Zahit Bolaman, et al.
Published: (2021)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
by: Hui Zheng, et al.
Published: (2021)

Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases
by: Omar Alhalabi, et al.
Published: (2021)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
by: Shansa Pranami E. Jayaweera, et al.
Published: (2021)

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
by: Gabriela Palma, et al.
Published: (2021)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
by: Nicolas Penel, et al.
Published: (2021)

Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB
by: Arumugam Nagalingam, et al.
Published: (2021)

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
by: Ayşe Hilal Eroğlu Küçükdiler, et al.
Published: (2021)

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Published: (2021)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
by: Weiping Liu, et al.
Published: (2021)

Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families
by: Thibaut S. Matis, et al.
Published: (2021)

Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
by: Wing H. Tong MD, PhD, MSc
Published: (2021)

Correction: Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation
by: Xiaoqing Fan, et al.
Published: (2021)

Author Response: Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients
by: Shunguo Zhang MB
Published: (2021)

Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
by: Laura Duran-Lozano, et al.
Published: (2021)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Published: (2021)

Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Published: (2021)

Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Published: (2021)

Correction: TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
Published: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
by: Federica Miglietta, et al.
Published: (2021)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Published: (2021)

Correction to: Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner
by: Shengming Deng, et al.
Published: (2021)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
by: Artem Gusak, et al.
Published: (2021)

Correction: Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer
Published: (2021)

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Published: (2021)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Published: (2021)

Correction to: ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma
by: Weipu Mao, et al.
Published: (2021)

Correction to: Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma
by: Aibin Liu, et al.
Published: (2021)

Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
by: Vincenza Conteduca, et al.
Published: (2021)

Correction to: Co-relation with novel phosphorylation sites of IκBα and necroptosis in breast cancer cells
by: Sung Hoon Choi, et al.
Published: (2021)

Correction: Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
Published: (2021)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Published: (2021)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Published: (2021)

Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Published: (2021)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Published: (2021)

Correction to: Hsa_circ_0005273 facilitates breast cancer tumorigenesis by regulating YAP1-hippo signaling pathway
by: Xuehui Wang, et al.
Published: (2021)